Javad Yazdani1, Mohhamad Ali Ghavimi1, Elahe Jabbari Hagh2, Farzin Ahmadpour3. 1. Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran. 2. Department of Internal Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran. Phoenixinfire@ymail.com.
Abstract
PURPOSE: In this study, we systematically investigated and analyzed articles focusing on the prognostic value of E-cadherin (E-cad) in human head and neck squamous cell carcinoma (HNSCC). METHODS: Searching through the different databases, the studies examining the associations between E-cad and HNSCC prognosis were identified. Outcomes such as disease-specific survival and overall survival were considered acceptable. Hazard ratio (HR) with 95% confidence interval (CI) was used to demonstrate prognostic value. RESULTS: A total of 40 studies were systematically analyzed, and finally, 1939 subjects were included in our meta-analysis. Our findings showed that significant aberrant expression of E-cad was associated with poor survival. However, some studies showed increased expression of E-cad in metastatic lesions was associated with poor prognosis. Alteration in location of E-cad expression also showed significant association with cancer survival, i.e., increased cytoplasmic E-cad. We conducted a meta-analysis on the eligible articles using a random effect model because of moderate heterogeneity. Strong association between aberrant expression of E-cad and poor survival was demonstrated (pooled HR = 2.28; 95% CI 1.78-2.91). CONCLUSIONS: Aberrant expression of E-cad may be a promising prognostic signature for HNSCC, especially when it is used with other prognostic markers.
PURPOSE: In this study, we systematically investigated and analyzed articles focusing on the prognostic value of E-cadherin (E-cad) in human head and neck squamous cell carcinoma (HNSCC). METHODS: Searching through the different databases, the studies examining the associations between E-cad and HNSCC prognosis were identified. Outcomes such as disease-specific survival and overall survival were considered acceptable. Hazard ratio (HR) with 95% confidence interval (CI) was used to demonstrate prognostic value. RESULTS: A total of 40 studies were systematically analyzed, and finally, 1939 subjects were included in our meta-analysis. Our findings showed that significant aberrant expression of E-cad was associated with poor survival. However, some studies showed increased expression of E-cad in metastatic lesions was associated with poor prognosis. Alteration in location of E-cad expression also showed significant association with cancer survival, i.e., increased cytoplasmic E-cad. We conducted a meta-analysis on the eligible articles using a random effect model because of moderate heterogeneity. Strong association between aberrant expression of E-cad and poor survival was demonstrated (pooled HR = 2.28; 95% CI 1.78-2.91). CONCLUSIONS: Aberrant expression of E-cad may be a promising prognostic signature for HNSCC, especially when it is used with other prognostic markers.
Authors: Antonio Greco; Armando De Virgilio; Maria Ida Rizzo; Fabio Pandolfi; Davide Rosati; Marco de Vincentiis Journal: Laryngoscope Date: 2015-10-29 Impact factor: 3.325
Authors: Erminia Massarelli; Erika Brown; Ngoc K Tran; Diane D Liu; Julie G Izzo; J Jack Lee; Adel K El-Naggar; Waun K Hong; Vassiliki A Papadimitrakopoulou Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Sung Woon Pyo; Mitsuyoshi Hashimoto; Young Sill Kim; Chang Hyen Kim; Sang Hwa Lee; Keith R Johnson; Margaret J Wheelock; Je Uk Park Journal: J Craniomaxillofac Surg Date: 2007-02-12 Impact factor: 2.078
Authors: G Pannone; A Santoro; A Feola; P Bufo; P Papagerakis; L Lo Muzio; S Staibano; F Ionna; F Longo; R Franco; G Aquino; M Contaldo; S De Maria; R Serpico; A De Rosa; C Rubini; S Papagerakis; A Giovane; V Tombolini; A Giordano; M Caraglia; M Di Domenico Journal: Curr Cancer Drug Targets Date: 2014 Impact factor: 3.428
Authors: Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García Journal: Cancers (Basel) Date: 2022-08-08 Impact factor: 6.575